Lymphomas

EMCL-Registry

Creation of a European mantle cell lymphoma registry

SAKK 38/23 LIBERTY

Non-Hodgkin B-cell lymphoma

Recruitment completed

HOVON 127/ SAKK 37/16

Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DAEPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma

Recruitment completed

IELSG-37

A randomized, open-label, multicentre, two-arm phase III comparative study assessing the role of mediastinal radiotherapy after Rituximab containing chemotherapy regimens to patients with newly diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL).

MorningLyte

MORNINGLYTE: international, multicenter phase III study to evaluate the efficacy and tolerability of mosunetuzumab in combination with lenalidomide compared to standard treatment in patients with previously untreated follicular lymphoma.

NX-5948-301

NX-5948-301 A Phase I study to determine the best dose(s) for the treatment of adult patients with B-cell lymphoma or leukemia who have relapsed and/or have not responded to other treatment with the investigational compound NX-5948, which degrades the enzyme Bruton's tyrosine kinase.

Recruitment completed

SAKK 38/19

SAKK 38/19 Therapy adjustment based on PET/CT and circulating tumor DNA in patients with diffuse large B-cell lymphoma

Recruitment completed

IELSG-47

MALIBU trial – Phase II study of combination ibrutinib and rituximab in untreated marginal zone lymphomas

IELSG-48

Phase 3, interventional, multicentre, open-label, randomized study comparing rituximab plus zanubrutinib to rituximab monotherapy in previously untreated, symptomatic splenic marginal zone lymphoma (RITZ)